BioDelivery Sciences International, Inc. announced the U.S. commercial launch and availability of ELYXYBTM (celecoxib oral solution), the first and only FDA-approved ready-to-use oral solution for the acute treatment of migraine with or without aura in adults. Migraine is a debilitating condition for almost 40 million people in the U.S. Many patients with migraine are searching for acute treatments that provide relief quickly and conveniently, without interfering with daily quality of life. ELYXYB is an oral solution of celecoxib, formulated using a self-microemulsifying drug delivery system (SMEDDS) that improves solubility and bioavailability leading to better absorption1.

This allows for the administration of a lower dose of drug to achieve therapeutic effect relative to a higher dose of the conventional oral capsule, which doesn't have the rapid onset of action that migraine patients need. ELYXYB comes in a small, single-dose bottle that does not require premixing, shaking, or measuring, making it convenient for patients to take immediately upon the onset of a migraine attack. BDSI is committed to ensuring access to appropriate patients who are prescribed ELYXYB.

The ELYXYB Passport Program provides access support and resources to both healthcare providers and patients, including a co-pay savings program.